The BEAM alliance announces new board of directors

January 16, 2017
BEAM Alliance, BEAM Alliance

Paris, 16 January 2017. The BEAM Alliance (Biopharmaceutical companies from Europe innovating in Anti-Microbial resistance research) today announces the election of its new Board of Directors further to its Extraordinary General Assembly held in Paris on 20 December 2016.

The five-member Board will be composed of the following Directors and Officers:

  • ·        President: Florence Séjourné, CEO Da Volterra (Paris, France) 

  • ·        Vice-President: Marc Gitzinger, CEO Bioversys, (Basel, Switzerland) 

  • ·        Secretary: Mark Jones, Head of Project Management, Basilea (Basel, Switzerland) 

  • ·        Treasurer: Holger Schmoll, CFO Aicuris (Wuppertal, Germany) 

  • ·        Officer: Marc Lemonnier, CEO Antabio (Toulouse, France)


The Board of Directors is elected for a period of three years and will be responsible for overall policy and direction of the BEAM Alliance in support of its mission to improve the regulatory, investment, and commercial environments in Europe for research, development, approval and market viability of new products combating antimicrobial resistance.

“It is truly a milestone for the BEAM Alliance that we have been able to formally become an association and furthermore to concretely establish our constitution” said Florence Séjourné, President of the BEAM Alliance. “I am pleased that the BEAM Alliance will be contributing to the groundbreaking innovations to combat AMR in Europe with our unique perspective as an association of SMEs dedicated to AMR wholeheartedly. We hope, as the board of directors, that the unified voice of the BEAM Alliance will strongly influence and stimulate AMR policy and incentives for new therapies.”


About the BEAM Alliance

BEAM represents European biopharmaceutical companies involved in developing innovative products to tackle antimicrobial resistance. BEAM collaborates with the existing community of stakeholders dedicated to implementing tangible strategies. BEAM gives its members a unique voice to propose and support policies and incentives in antimicrobial research and development in Europe.